In pharma arguments, high stakes for generic drug makers

Nearly two years ago, the Supreme Court ruled that manufacturers of generic drugs were immune from liability in "failure to warn" lawsuits in state courts, in part because under federal law, generics are powerless to have warnings or labels that are different from their brand-name counterparts.

This article requires premium access

This article requires premium access to The National Law Journal. Please sign in or subscribe to read the full text.